Credo Technology Group Holding Ltd vs Medtronic PLC — how do they compare? Credo Technology Group Holding Ltd trades at $270 (market cap $46.19B), while Medtronic PLC trades at $90.37 (market cap $116.07B). The key difference: Medtronic PLC is far larger — about 2.5× Credo Technology Group Holding Ltd's market cap, and Medtronic PLC pays a 3.18% dividend while Credo Technology Group Holding Ltd pays none. Which is the better fit depends on your goals.
| CRDO | MDT | |
|---|---|---|
Market Cap | $46.19B | $116.07B |
Sector | Technology | Health |
52-Week High | $302.52 | $105.35 |
52-Week Low | $87.81 | $73.75 |
Enterprise Value | $44.77B | $134.82B |
Dividend Yield | — | 3.18% |
Signals from Pluang's Aura AI — not financial advice
CRDO trades at $257.10, up 7.15% today, with strong bullish momentum supported by technical indicators and positive analyst sentiment. The stock shows robust fundamentals with 157% revenue growth in Q4 2025 and consistent earnings beats. Recent news highlights Credo's strategic positioning in AI infrastructure, including contributions to the Open Compute Project and institutional investment increases.
Outlook remains positive with 86.7% analyst buy ratings and a $285.42 consensus price target, though premium valuations (P/E 98.7) and recent insider selling warrant caution. Key risks include customer concentration and execution challenges in the competitive AI hardware space.
Medtronic (MDT) trades at $89.99, up 0.65% with strong technical momentum and bullish moving average signals. The company demonstrates solid fundamentals with consistent earnings beats, 13.2% net income margin, and positive cash flow trends. Recent product innovations including the Hugo robotic surgery platform and AI surgical tools position MDT for growth. Analyst consensus remains strongly positive with 60% buy ratings and $98.75 price target.
MDT presents a compelling investment case with steady revenue growth, dividend aristocrat status, and technological leadership in medical devices. Key risks include increasing debt levels and competitive pressures from Intuitive Surgical. The stock's current valuation at 24.31 P/E appears reasonable given growth prospects, with upside potential to consensus targets if execution continues.
Trailing returns across standard periods
Latest headlines on both assets
Credo Technology provides high-speed connectivity solutions for AI-driven applications and hyperscale data centers. Its products enable faster, more energy-efficient data transmission for cloud and telecom infrastructure.
Read more on CRDO →One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →